OPNT - オピアント・ファ―マシュ―ティカルズ （Opiant Pharmaceuticals Inc.）

Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations…

Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q2 GAAP EPS of -$2.31 misses by $0.95.Revenue of $3.89M (-65.5% Y/Y) misses by $0.77M.

SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update. Recent highlights include:

Opiant Pharmaceuticals (OPNT) is scheduled to announce Q2 earnings results on Thursday, August 11th, after market close.The consensus EPS Estimate is -$1.36 and the consensus…

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy Mersana Therapeutics Inc (NASDAQ: MRSN ) announced a global collaboration that provides GSK plc (NYSE: GSK ) an exclusive option to co-develop and commercialize XMT-2056. Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the U.S. Clearside Biomedical Secures Non-Dilutive fUNDING fROM HealthCare Royalty Partners Clearside Biomedical Inc (NASDAQ: CLSD ) has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners. Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million . At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.

Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations…

Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q2 GAAP EPS of -$2.31 misses by $0.95.Revenue of $3.89M (-65.5% Y/Y) misses by $0.77M.

SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update. Recent highlights include:

Opiant Pharmaceuticals (OPNT) is scheduled to announce Q2 earnings results on Thursday, August 11th, after market close.The consensus EPS Estimate is -$1.36 and the consensus…

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy Mersana Therapeutics Inc (NASDAQ: MRSN ) announced a global collaboration that provides GSK plc (NYSE: GSK ) an exclusive option to co-develop and commercialize XMT-2056. Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the U.S. Clearside Biomedical Secures Non-Dilutive fUNDING fROM HealthCare Royalty Partners Clearside Biomedical Inc (NASDAQ: CLSD ) has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners. Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million . At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.

Opiant Pharmaceuticals (OPNT) on Wednesday said it would expand its long-term collaboration with Aptar Pharma for the making of Aptar''s nasal Unidose device to be used in the production…

Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003 Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003

Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q1 2022 Results Conference Call May 10, 2022 04:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor…

Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%.

Opiant Pharmaceuticals press release (OPNT): Q1 GAAP EPS of -$2.43 misses by $1.68.Revenue of $4.47M (-30.0% Y/Y) misses by $1.43M.